Intravenous tPA administration in patients with acute ischemic stroke: Edirne experience

Basit Öğe Kaydı
dc.authorscopusid8921557300
dc.authorscopusid6602822048
dc.authorscopusid55931238700
dc.authorscopusid57204250472
dc.contributor.authorAsil T.
dc.contributor.authorBalci K.
dc.contributor.authorUtku U.
dc.contributor.authorIr N.
dc.date.accessioned2024-06-12T10:28:43Z
dc.date.available2024-06-12T10:28:43Z
dc.date.issued2011
dc.description.abstractObjective: Intravenous (IV) thrombolytic therapy is the only approved effective treatment used in patients with acute ischemic stroke. In this study, we aimed at establishing the clinical outcomes of the IV tissue plasminogen activator (tPA) therapy and the main factors affecting the success rate of the treatment. Patients and Methods: Demographic data, radiological and clinical findings of the patients with acute ischemic stroke who were administered IV tPA therapy in our clinic were recorded. During the first 90 days, symptomatic intracranial hemorrhage and death events were reported. On day 90, patients were divided into two groups; patients with 0-2 MRS scores were deemed to have a good prognosis, while patients with 0-1 MRS score were deemed to have an excellent prognosis. The next step was to analyze the factors which affected disease prognosis. Results: The study included 48 patients with acute ischemic stroke. Patients were administered IV tPA therapy between November 2006 and January 2010. The mean age was 64,8±12,8 and the mean NIH score was 16,8±5,2. In addition, the mean ASPECT score was 6,7±2,5 based on the baseline CT scan. A total of 9 (18%) of the patients died within the first 90 days, including 2 (4%) patients with symptomatic intracranial hemorrhage. On day 90, 11 patients (23%) had an excellent prognosis, whereas 22 (46%) had a good prognosis. In the study, baseline NIH scores and ASPECT scores were associated with a good prognosis. Conclusion: Intravenous tPA therapy is an approved therapeutic modality in patients with acute ischemic patients, which prevents disability, although it does not decrease mortality. Our study results suggesting that IV tPA therapy was an effective treatment in patients with acute ischemic disease were also consistent with previous significant study findings.en_US
dc.identifier.endpage321en_US
dc.identifier.issn1300-1817
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-80052753581en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage317en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17365
dc.identifier.volume28en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherEge University Pressen_US
dc.relation.ispartofJournal of Neurological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectClinical Outcomes; Ischemic Stroke; Thrombolytic Therapyen_US
dc.subjectTissue Plasminogen Activator; Article; Brain Hemorrhage; Brain Ischemia; Clinical Article; Computer Assisted Tomography; Human; Prognosisen_US
dc.titleIntravenous tPA administration in patients with acute ischemic stroke: Edirne experienceen_US
dc.title.alternativeAkut i?skemik i?nmeli hastalarda IV tPA kullanımı: Edirne deneyimien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu